Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532226) titled 'A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants' on April 8.
Study Type: Observational
Primary Sponsor: Janssen-Cilag Ltd.
Condition:
Arthritis, Psoriatic
Recruitment Status: Not recruiting
Date of First Enrollment: April 13, 2026
Target Sample Size: 200
To know more, visit https://clinicaltrials.gov/study/NCT07532226
Disclaimer: Curated by HT Syndication....